Hyperbaric oxygen therapy (HBOT) involves placing the patient in a chamber with 2–3 atmospheres of pure oxygen, dramatically increasing oxygen levels in blood and tissues.
In cancer care, it is not a primary treatment for the tumour itself but serves as a valuable supportive therapy to alleviate side effects, improve quality of life, and in some cases enhance treatment effectiveness.
In the past, cancer treatment was often “one-size-fits-all”:
patients with the same type of lung, breast, or colorectal cancer received largely similar protocols.
But growing evidence shows that every tumour has a unique genetic expression, signalling pathways, and drug response — as individual as a fingerprint.
Personalised treatment plans have emerged to shift care from “generally effective” to “precisely targeted”.
Many people believe palliative supportive care is only for late-stage patients, but in reality, it can play a valuable role from the moment of diagnosis, throughout treatment, and into recovery.
Palliative supportive care is not “giving up on active treatment” — it runs alongside chemotherapy, radiotherapy, targeted therapy, or immunotherapy as a gentle ally.
Its simple goal: manage pain, side effects, and emotional burden so you can focus your energy on fighting the disease rather than battling discomfort.
Iron deficiency after chemotherapy is experienced by more than 50 % of patients.
Chemotherapy drugs not only suppress bone-marrow blood production but also cause gut absorption issues, chronic blood loss, or inflammatory consumption, rapidly depleting iron stores.
Iron is not just the “raw material for haemoglobin” — it is essential for oxygen transport, energy production, and immune function.
When iron is low, your body signals the need for replenishment through these symptoms.
Hypoalbuminemia (serum albumin <3.5 g/dL) is one of the most common nutritional issues during and after cancer treatment. It is not just a “low number” — it can lead to oedema, fatigue, slow wound healing, reduced immunity, and even affect the ability to continue treatment. Understanding the typical stages when it occurs allows you and your physician to prevent and manage it proactively.
After cancer treatment ends, many patients find that “appetite just doesn’t come back”:
food looks unappealing, a few bites feel filling, or even the smell triggers nausea.
This is not due to “lack of effort” — it is the result of treatment affecting multiple body systems and temporarily disrupting appetite regulation.
Understanding these common causes can reduce self-blame and open the door to more targeted ways to improve.
Walking through this valley together with the gentlest care
When a family member is diagnosed with cancer, you may notice they no longer laugh as easily, talk less, sleep poorly, or sometimes fall silent or tear up unexpectedly.
These low moods are completely normal — they are not only facing the illness itself, but also the uncertainty, loss of control, and guilt towards family.
As a caregiver, your role is not to “force them to cheer up”, but to let them know: their feelings are seen, accepted, and allowed to exist.
Cancer-related fatigue (CRF) after chemotherapy is experienced by more than 70–90 % of patients.
It is not ordinary tiredness — sleeping more does not fully resolve it, because it involves disrupted mitochondrial function, high oxidative stress, persistent low-grade inflammation, nutrient depletion, and hormonal changes working together.
Let you clearly know “how your immunity is right now” — no longer just a feeling
Many cancer patients, after treatment or during long-term follow-up, most often ask:
“Has my immunity recovered yet?”
Conventional blood tests showing white blood cell or lymphocyte counts can only tell you “normal” or “low”,
but cannot reveal the overall “fighting strength” of your immune system at this moment.
In the field of modern oncology, early detection and personalized treatment have become key to improving survival rates and quality of life for patients. RGCC (Research Genetic Cancer Centre) testing is a series of advanced blood-based assays that require only a single blood draw to analyze circulating tumor cells (CTCs) and related biomarkers. These tests provide critical insights into the presence, progression, and treatment response of cancer, helping physicians create truly tailored treatment plans. The three most commonly used tests—Oncotrace, Onco-D-clare, and Onconomics Plus—excel in monitoring, screening, and treatment optimization, respectively.